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A therosclerosis is regarded as a chronic inflammatory disease of the vessel wall, characterized by an intimal accumulation of immune cells at sites of plaque formation, leading to the progressive narrowing of the arterial lumen. [1] [2] [3] A prominent role herein has been ascribed to macrophages, which accumulate oxidized low-density lipoprotein (oxLDL) and other lipids and transform into foam cells within the arterial wall. [1] [2] [3] [4] However, polymorphonuclear neutrophilic leukocytes (PMN) constituting the most abundant white blood cells in the circulation have also recently been associated with the development of atherosclerosis. Although systemic PMN counts correlate with the severity of atherosclerosis and PMN localize at sites of plaque rupture and erosion in patients with acute coronary syndromes and symptomatic plaques, 1, 3, [5] [6] [7] [8] [9] PMN were also localized in murine atherosclerotic plaques, and increased peripheral PMN numbers associated with aggravated atherosclerosis and inflammation in murine models of atherosclerosis. [10] [11] [12] Interferon regulatory factor 8 (IRF8) (also known as interferon consensus sequence binding protein) is exclusively expressed in hematopoietic cells and critical in lineage determination and the development of myeloid cells from common progenitor cells. Although essential in directing monocyte and macrophage differentiation, IRF8 represses genes promoting granulocytic differentiation and maturation. [13] [14] [15] In consequence, IRF8-deficient (IRF8 −/− ) or IRF8 mutant mice develop a chronic myelogenous leukemia (CML)-like syndrome with a striking increase in PMN numbers whereas cells bearing monocyte/macrophage markers are reduced and functionally compromised.
Given the important contribution of PMN to atherosclerosis and neutrophilia to be a hallmark of human CML, we addressed atherosclerotic lesion formation in atherosclerosis-prone IRF8 −/− mice in hematopoietic cells that develop a CML-like disease.
Methods
Please see Methods in the online-only Data Supplement.
Mouse Models
Six-to 8-week-old female recipient apolipoprotein E-deficient (apoE − 13 (all C57BL/6 background) after an ablative dose of whole body irradiation, and were fed a standard western diet containing 21% fat and 0.15% cholesterol (Altromin). PMN were depleted by intraperitoneal injections of monoclonal antibody RB6-8C5 every other day. A subcutaneous air pouch 18 was created in IRF8 +/+ or IRF8 −/− mice, and injected with platelet-activating factor. Peritonitis was induced by intraperitoneal injection with thioglycollate. 19, 20 Cells were collected from lavage fluids, and processed for fluorescence activated cell sorter (FACS) analysis.
Atherosclerotic Lesion Quantification and Immunohistochemistry
Atherosclerosis and lipid accumulation were assessed in aortic roots and thoracoabdominal aortas by staining for lipid depositions with Oil Red O ( Figure I in the online-only Data Supplement). 19 The relative content of macrophages, T cells, smooth muscle cells, and PMN 19 were determined by staining with specific monoclonal antibody or appropriate isotype controls. Apoptotic nuclei were detected by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Collagen was stained using Sirius Red.
Flow Cytometry, Cell Sorting, and ELISA
After staining with directly conjugated antibodies, FACS analysis and cell sorting were performed using a FACSCanto II or FACSAria. Interleukin-10 (IL-10) concentrations were determined using the mouse IL-10 DuoSet ELISA Kit (R&D).
Analysis of Myeloperoxidase and Matrix Metalloproteinase-9 Activity and Reactive Oxygen Species Formation
Myeloperoxidase (MPO) activity was measured as described. 18, 20 Matrix metalloproteinase (MMP)-9 activity was quantified using the SensoLyte MMP-9 assay kit and reactive oxygen species (ROS) formation determined by analyzing the fluorescence of PMN loaded with 2′,7′-dichlorodihydrofluorescein diacetate before and after tumor necrosis factor-α or phorbol myristate acetate stimulation.
Apoptosis, Cell Cycle Assays, and Phagocytosis
Cell staining with Annexin V or propidium iodide and the uptake of 1,1′-dioctadecyl-3,3,3'3'-tetra-methylindocyanide percholoratelabeled oxLDL or calcein-labeled apoptotic PMN by peritoneal macrophages were analyzed by FACS.
Statistics
Data are represented as mean±SD, and were analyzed by Student t test, ANOVA with Tukey multiple comparison test, nonparametric Mann-Whitney test, or Kruskal-Wallis test with Dunn post hoc test (Prism 4.0 software, GraphPad), as appropriate. Data for ROS measurement were analyzed with 2-way repeated measures ANOVA (treatment time) followed by planned comparisons. P<0.05 was considered to be statistically significant. Figure 1D ). This is in line with a chronic disease course with no signs of an accumulation of progenitor or immature myeloid cells in blood, characteristic of the late progressive blast phase. 13 Figure 2C) . Moreover, the expression of MPO, an enzyme stored in PMN granules, as well as the frequency of MMP-9 + cells 10, 11, 23 was found to be increased ( Figure IIIA 
Results
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Impairment of Macrophage Function But Not Accumulation in IRF8 −/− Mice
Despite an increase in the total number of leukocytes accumulating in air pouches of IRF8 −/− mice in response to platelet-activating factor after 4 hours and a significant decrease in relative frequencies of monocytes, the absolute number of monocytes extravasated into the air pouch did not differ in IRF8 +/+ or IRF8 −/− mice, contrasting decreased monocyte counts in peripheral blood ( Figure 3A and 3B) . Likewise, no differences in macrophage numbers were observed in the peritoneum of untreated mice or at 4 days after thioglycollate injection when comparing IRF8 +/+ and IRF8 −/− mice ( Figure 3C ). The rate of apoptosis and proliferation of peritoneal macrophages did not differ between IRF8 −/− and IRF8 +/+ mice, and was not altered in response to oxLDL, a stimulus relevant in atherogenesis ( Figure V in the online-only Data Supplement). These data suggest that inflammatory monocyte recruitment in the acute or chronic setting and apoptosis of macrophages is not impaired by IRF8 deficiency.
To address an IRF8-related impact on macrophage phenotype, we further analyzed the surface expression of major histocompatibility complex class II, costimulatory molecule CD40 and scavenger receptors in peritoneal macrophages from IRF8 +/+ or IRF8 −/− mice by FACS analysis. The expression of major histocompatibility complex class II, CD40, and surface class B scavenger receptor CD36 was significantly decreased in IRF8 −/− macrophages compared with IRF8 +/+ controls whereas the expression of class A scavenger receptors CD68 and CD204 was not affected ( Figure 4A and 4B).
In accordance with a prominent role of CD36 in the uptake of oxLDL and the clearance of apoptotic cells, 24,25 a significantly decreased phagocytosis of labeled oxLDL and efferocytosis of apoptotic PMN was observed in IRF8 −/− in comparison with IRF8 +/+ macrophages, as determined by FACS analysis ( Figure  4C ). Phagocytosis of apoptotic cells was shown to exert immunosuppressive effects by inducing the production of antiinflammatory cytokines including IL-10 in phagocytes. 26, 27 Compared with a strong secretion of IL-10 by IRF8 +/+ macrophages in response to the uptake of apoptotic PMN, the release of IL-10 was substantially impaired in IRF8 −/− macrophages in line with diminished phagocytic capacities ( Figure 4D ). These differences may also relate to reduced IL-10 serum levels in 
Inflammatory Accumulation of IRF8 −/− PMN Is Due to Enhanced Extravasation
The enhanced frequency of PMN in apoE −/− mice reconstituted with IRF8 −/− BM in aortic root plaques led us to further address the recruitment of PMN. Similarly, the number of emigrated PMN in the air pouch lavage in response to platelet-activating factor was significantly increased in IRF8 −/− mice after 4 hours ( Figure 5A ). However, the ratio of PMN numbers in blood relative to air pouches was identical in either strain (0.37±0.04 in IRF8 +/+ versus 0.40±0.09 in IRF8 −/− mice), suggesting that PMN are recruited with similar efficiencies and that their enhanced accumulation at sites of inflammation in mice with IRF8 −/− BM reflects an influx proportional to their numbers in blood.
An increased frequency of apoptotic PMN in apoE −/− mice reconstituted with IRF8 −/− BM ( Figure 2 ) may indicate an enhanced susceptibility of IRF8 −/− PMN to undergo cell death. Although both blood and air pouch-derived IRF8 −/− PMN tended to undergo apoptosis less frequently early after the induction of serum starvation, no differences could be detected after 36 hours with ≈50%-Annexin V + apoptotic PMN, and at later time points, as revealed by FACS analysis and when compared with IRF8 +/+ PMN ( Figure 5B ). Of note, BM-derived IRF8 −/− PMN were less susceptible to apoptosis compared with IRF8 +/+ controls (not shown), confirming previous findings. 16 Enhanced proliferation of immature extravasated PMN may yet be another mechanism contributing to PMN accumulation in myeloproliferation. Cell cycle analysis of PMN from blood and air pouches of IRF8 +/+ and IRF8 −/− mice, however, did not reveal any differences in the number of proliferating cells in the synthesis and mitosis phase, excluding this possibility ( Figure 5C ). This indicates that apoptosis and proliferation of PMN in blood and at sites of inflammation are not substantially affected by the lack of IRF8. Thus, increased numbers of PMN and TUNEL + PMN in atherosclerotic lesions are likely due to an overflow of extravasated PMN.
ROS Formation and Granule Discharge Are Not Impaired in IRF8
−/− PMN ROS play a central role in the development of atherosclerosis, and initiate and sustain key mechanisms of atheroprogression.
28
Because PMN are a major source of ROS, we assessed the ROS-forming aptitude of peripheral PMN sorted from blood and BM. Both the treatment with tumor necrosis factor or phorbol myristate acetate triggered an equal release of ROS over baseline in IRF8 +/+ compared with IRF8 −/− PMN ( Figure 5D ). PMN contain preformed granules, which are rapidly released on extravasation. This process can be assessed by the upregulation of membrane-bound receptors translocated from the granule membrane or by measurement of granule proteins in the cell-free supernatant. 18, 20, 29 Compared with circulating blood PMN, the surface expression of CD11b and CD14 derived from secretory vesicles and tertiary granules 29 were markedly upregulated on both IRF8 +/+ and IRF8 −/− PMN after extravasation to the air pouch ( Figure 5E ). Concentrations of MMP-9 and MPO, which are stored in primary and secondary PMN granules, 29 were found to be significantly increased in the air pouch lavage from IRF8 −/− compared with IRF8 +/+ mice ( Figure 5F , left). However, no significant differences in the amount of enzymes released per PMN were observed between both strains in the air pouch ( Figure 5F , right). This indicates that IRF8 −/− PMN are functionally intact, and that enhanced numbers of extravasated PMN likely contribute to an overall increased ROS-and granule-releasing capacity.
PMN Depletion in IRF8 −/− BM Recipients Prevents Aggravated Atherosclerotic Lesion Formation
To scrutinize the contribution of PMN to aggravated lesion formation in mice reconstituted with IRF8 −/− BM, a PMNdepleting antibody was used ( Figure VII Table I in the online-only Data Supplement). These data establish that the expansion of PMN in blood and at sites of inflammation critically contributes to atherosclerotic lesion formation in mice with IRF8 −/− BM.
Discussion
In this article, we show that the development of a CML-like syndrome in apoE −/− and LDLR −/− mice transplanted with IRF8 −/− or IRF8 −/− apoE −/− BM is associated with a striking increase in atherosclerotic lesion formation compared with mice reconstituted with IRF8 +/+ control BM. The marked expansion of functionally intact PMN in peripheral blood was accompanied by their enhanced accumulation but also apoptosis at sites of inflammation and an accelerated necrotic core formation and plaque growth in IRF8 −/− BM recipients.
IRF8
−/− PMN were functionally intact, entailing an enhanced release of ROS and granule components at sites of inflammation. Despite a reduction in circulating monocyte numbers, the accumulation of macrophages during inflammation was unaffected by IRF8 deficiency, but associated with an altered macrophage phenotype, as revealed by a diminished efferocytosis of apoptotic PMN and an impaired IL-10 cytokine release. By demonstrating that the depletion of circulating PMN retarded necrotic core formation and prevented the exacerbation of plaque growth in IRF8 −/− BM-recipient LDLR −/− or apoE −/− mice, we pinpointed PMN to critically contribute to accelerated atherosclerotic lesion formation in CML-like disease. Although lesion formation was attenuated in apoE −/− mice transplanted with apoE +/+ compared with apoE −/− BM, supporting the notion that the secretion of apoE by BM-derived macrophages protects apoE −/− mice from diet-induced atherosclerosis, deficiency in IRF8 in BM consistently resulted in accelerated lesion formation irrespective of the mouse model used, strengthening the general validity of our findings.
Emerging evidence suggests that PMN play a critical role in atherosclerosis. [1] [2] [3] [10] [11] [12] 30, 31 We have previously shown that increased numbers of circulating and lesional neutrophils aggravated diet-induced atherosclerosis in apoE −/− and LDLR −/− mice. 10 Moreover, neutrophilia induced by hyperlipidemia could be related to accelerated atherosclerotic lesion formation in apoE −/− mice. 12 In these studies, depletion of neutrophils reversed early atherosclerotic lesion formation, establishing an important role of this cell type in atherosclerosis. Similarly, transplantable myeloproliferative disease in ATP-binding cassette transporter-deficient Abca1 −/− and Abcg1 −/− mice, associated with leukocytosis and neutrophilia, enhanced atherosclerosis. 32 The accumulation of neutrophils in human atherosclerotic plaques associates with characteristics of rupture-prone lesions, 28 and circulating PMN counts correlate with cardiovascular complications. 33, 34 It remains to be elucidated, however, whether patients with myeloproliferative diseases such as CML and long-standing neutrophilia would be more prone to atherosclerosis. Clinical reports on the association of CML with atherosclerosis or its consequences are scarce. One study including a small number of patients found an association of coronary artery disease with coexisting myeloproliferative syndromes, which was not significant after adjustment for various risk factors. 35 Several reasons may account for the limited insight into potential consequences of CML-like disease on atherosclerosis in patients. CML is an age-related disease with an increased prevalence in elderly people. These patients may already suffer from cardiovascular complications of multifactorious origins, making it impossible to investigate the impact of CML as an independent risk factor. In addition, effective treatment regimens for CML are available. Decreased IRF8 expression was demonstrated in both humans and mice with CML. 36, 37 Interestingly, a mutation of the IRF8 gene was recently associated with high neutrophil counts and an absence of monocytes, 38 resembling the phenotype of mice with loss of IRF8. Therapeutics often aim at elevating IRF8 expression, eg, treatment with interferon-α stimulates the expression of IRF8, and in consequence partially reverses CML, and therapy with imatinib mesylate inhibits the tyrosine kinase activity encoded by the breakpoint cluster region-Abelson (BCR-ABL) fusion gene and subsequently restores IRF8 expression, inducing a complete cytogenic response in 80% of patients with CML in the chronic phase. 22 In this regard, it is important to note that treatment with imatinib was shown to reduce diabetes mellitus-associated atherosclerosis in mice, 39 and preliminary experiments indicate that administration of imatinib lowered the numbers of PMN in peripheral blood of BL6 mice (Yvonne Döring and Alma Zernecke, unpublished observation, 2010).
The immune cell infiltration of the vessel wall is a crucial force driving atherosclerosis. [1] [2] [3] [4] Through the expression of scavenger receptors, macrophages participate in the phagocytic uptake of lipids and their retention in the vessel wall, as well as in the clearance of apoptotic cells. 2, 3, 24, 25 Although surface expression of scavenger receptors CD68 and CD204 was unaltered, CD36 was markedly reduced in IRF8 −/− macrophages. Known to account for up to 70% of the accumulation of oxLDL in macrophage foam cells, 24 these differences might at least, in part, explain the impaired uptake of oxLDL by IRF8 −/− macrophages in vitro, and an increased accumulation of extracellular lipid deposits in plaques of IRF8 −/− BM-recipient mice. Interestingly, although deletion of CD36 was shown to protect from atherosclerosis, 40 an impaired clearance of apoptotic material has been associated with disease acceleration and a reduction in IL-10 production. 26 Accordingly, diminished IL-10 protein levels were observed in the supernatants of IRF8 −/− macrophages in response to an impaired efferocytosis of apoptotic PMN and in sera of apoE −/− mice carrying IRF8 −/− BM.
The depletion of monocytes/macrophages in mice expressing the diphtheria toxin receptor under the control of CD11b or the reduction in blood monocyte levels due to the lack of important mobilization or survival cues was shown to reduce early plaque burden. [41] [42] [43] [44] However, despite a marked reduction in circulating monocyte numbers in mice with IRF8 −/− BM, unaltered acute and chronic recruitment of monocytes to the inflammatory air pouch and peritoneum, and unchanged macrophage plaque content were observed. This likely precludes severe functional deficits in the migratory capacity of IRF8 −/− monocytes per se. An enhanced survival of IRF8 −/− macrophages masking defects in extravasation is unlikely to occur under inflammatory conditions, because previous findings showed a reduction in the susceptibility to apoptosis in IRF8 −/− myeloid cells under homeostatic conditions but not on inflammatory stimulation. 16 Accordingly, we did not detect any differences in the frequency of apoptosis in IRF8 −/− macrophages in the peritoneum and in response to oxLDL in vitro, and in atherosclerotic lesions of apoE −/− mice reconstituted with IRF8 −/− BM. However, augmented PMN extravasation and PMN-induced inflammation in mice reconstituted with IRF8 −/− BM may provide excessive recruitment cues that enhance subsequent monocyte influx. For instance, ROS formation was unaltered in IRF8 −/− PMN, constituting a weapon being at the immediate demand of PMN and proposed to be a key mediator in atherosclerosis. 28 PMN produce large amounts of ROS via MPO, lipoxygenases, and nicotinamide adenine dinucleotide phosphate oxidase. In addition to triggering the production of proinflammatory cytokines, PMN-derived ROS may act through an enhancement of the expression of endothelial adhesion molecules (contributing to leukocyte recruitment), the induction of apoptosis of endothelial cells, or lipid oxidation within lesions (with oxLDL functioning as a strong proinflammatory mediator). 28, 45 This enhanced inflammatory environment within plaques of IRF8 −/− BM-recipient mice, as also epitomized by an increased expression of the intercellular adhesion molecule 1, may drive monocyte recruitment to lesions and compensate for reduced peripheral monocyte counts.
In addition, emigrated PMN release preformed granule components, which can trigger the subsequent recruitment and attraction of inflammatory monocytes by involvement of formyl peptide receptors 18 but can also promote proinflammatory responses in monocytes/macrophages. 20, 46 Monocytes/ macrophages accumulating at sites of inflammation may thus contribute to accelerated atherogenesis in mice reconstituted with IRF8 −/− BM. The activation of PMN and the discharge of granule proteins were not impaired, as determined by the rapid upregulation of CD11b and CD14 on extravasated IRF8 −/− PMN, or by the release of MPO and MMP-9 from primary and secondary granules. MPO can limit the bioavailability of NO, and can therefore contribute to the onset of endothelial dysfunction. 47 It was also reported that MPO-generated hypochlorous acid may contribute to intracoronary endothelial cell desquamation and the engenderment of a prothrombotic phenotype. 48 Due to its proteolytic function, MMP-9 was furthermore shown to contribute to the degradation and weakening of the fibrous cap ultimately promoting a vulnerable plaque phenotype and plaque rupture. −/− mice, and to be proportional to circulating PMN counts. Because no differences in PMN numbers were observed in the air pouch or the peritoneum in IRF8 +/+ compared with IRF8 −/− mice under physiological conditions or without inflammation, these findings suggest that peripheral PMN numbers determine the rate of extravasation in the context of inflammation and atherosclerosis. The rapid PMN mobilization and leukocytosis under inflammatory conditions might thus constitute a universal mechanism imposing an enhanced PMN influx at sites of inflammation. In the context of myeloproliferative diseases, however, this might implicate an acceleration of atheroprogression.
PMN are short-lived phagocytes undergoing rapid apoptosis after emigration. The rate of apoptosis of blood or emigrated PMN was not different in IRF8
−/− compared with control mice. However, likely due to their enhanced accumulation, apoptotic PMN were detected in increased numbers in atherosclerotic plaques. The impaired clearance of apoptotic cells and an overload of reduced phagocytic capacities of macrophages with dying PMN in mice carrying IRF8 −/− BM might in consequence lead to necrosis, secondary inflammation, and necrotic core formation. Support for this notion stems from the prevention of enlarged necrotic core formation in LDLR −/− and apoE −/− mice reconstituted with IRF8 −/− and IRF8
BM, respectively, and depleted of PMN. Depletion of PMN abolishes continuous neutrophil influx. However, such treatment can also reduce neutrophil counts in BM (Oliver Soehnlein, unpublished observations, 2011), suggesting that PMN depletion may also directly target tissueresident neutrophils within lesions.
IRF8 plays a crucial role in the development and functionality of dendritic cells. [50] [51] [52] Mice lacking dendritic cells due to a constitutive cell-specific expression of a suicide gene develop a myeloproliferative disorder, likely attributable to increased FMS-like tyrosine kinase 3 ligand serum levels. Notably, FMS-like tyrosine kinase 3 ligand serum levels are similarly increased in IRF8 −/− mice. 53 Although the impact of dendritic cells on atherosclerosis remains to be fully elucidated, 54 an impaired functionality of dendritic cells in IRF8 −/− mice may thus contribute to myeloproliferation and atherogenesis.
Taken together, our data for the first time show that the expansion of PMN in myeolproliferative syndromes or related conditions may give rise to enhanced atherosclerosis. In mice with IRF8 −/− BM, functionally intact PMN may initiate vascular damage and atherogenesis. In addition, their continuous influx might exacerbate inflammation in the local plaque environment aggravating disease progression and necrotic core formation in alliance with a defect in macrophage clearance of apoptotic cells and anti-inflammatory functions. However, functional impairments in monocytes/macrophages and dendritic cells or other cell types in IRF8 −/− mice may additionally contribute to exacerbated lesion formation. Further clinical studies are warranted to scrutinize the possibility of an enhanced susceptibility to atherosclerosis in patients with myeloproliferative disorders.
